Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedFooter revision updated to v3.3.2, replacing v3.2.0.SummaryDifference0.0%

- Check28 days agoChange DetectedRemoved the banner that stated potential delays due to government funding and NIH operating status from the page; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedThe record history now shows additional submission versions, expanding the list of past updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check71 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference8%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.2%

- Check93 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element has been removed.SummaryDifference0.5%

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.